-
公开(公告)号：US20210277009A1
公开(公告)日：2021-09-09
申请号：US17266474
申请日：2019-08-05
Applicant: David WITTER , Shuhei KAWAMURA , Michelle MACHACEK , Ryan QUIROZ , Michael H. REUTERSHAN , Sebastian SCHNEIDER , Phieng SILIPHAIVANH , Yingchun YE , Charles S. YEUNG , Merck Sharp & Dohme Corp.
Inventor： David Witter , Shuhei Kawamura , Michelle Machacek , Ryan Quiroz , Michael H. Reutershan , Sebastian Schneider , Phieng Siliphaivanh , Yingchun Ye , Charles S. Yeung
IPC: C07D487/04 , C07D519/00
Abstract: The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
-
公开(公告)号：US08962611B2
公开(公告)日：2015-02-24
申请号：US14465577
申请日：2014-08-21
Applicant: Merck Sharp & Dohme Corp.
Inventor： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Michael D. Altman , Stephane L. Bogen , Ronald J. Doll
IPC: A61K31/553 , C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D471/08 , C07D498/04 , C07D519/00
Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Abstract translation: 本发明提供如本文所述的取代的咪唑并吡啶或其药学上可接受的盐或溶剂化物。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
公开(公告)号：US08846657B2
公开(公告)日：2014-09-30
申请号：US14132946
申请日：2013-12-18
Applicant: Merck Sharp & Dohme Corp.
Inventor： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Michael D. Altman , Stephane L. Bogen , Ronald J. Doll
IPC: A61K31/553 , C07D471/04 , C07D471/08 , C07D498/04
CPC classification number: C07D471/04 , C07D471/08 , C07D498/04 , C07D519/00
Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Abstract translation: 本发明提供如本文所述的取代的咪唑并吡啶或其药学上可接受的盐或溶剂化物。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
公开(公告)号：US20210309687A1
公开(公告)日：2021-10-07
申请号：US17266515
申请日：2019-08-05
Applicant: Michelle MACHACEK , David WITTER , Chunhui HUANG , Shuhei KAWAMURA , Sebastian SCHNEIDER , Mrray WAN , Merck Sharp & Dohme Corp.
Inventor： Michelle Machacek , David Witter , Chunhui Huang , Shuhei Kawamura , Sebastian Schneider , Murray Wan
Abstract: The present invention provides a compound of formula (I) Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, are PRMT5 inhibitors. Also provided are methods of making compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
-
公开(公告)号：US20150368247A1
公开(公告)日：2015-12-24
申请号：US14764616
申请日：2014-02-04
Applicant: Matthew P. CHRISTOPHER , Francesc Xavier FRADERA LLINAS , Michelle MACHACEK , Michelle MARTINEZ , Michael Hale REUTERSHAN , Manami SHIZUKA , Binyuan SUN , Christopher Francis THOMPSON , Wesley B. TROTTER , Matthew E. VOSS , Liping YANG , Merck Sharp & Dohme Corp.
Inventor： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Liping Yang
IPC: C07D473/34 , C07D473/00 , C07D473/30
CPC classification number: C07D473/34 , C07D473/00 , C07D473/30
Abstract: The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Abstract translation: 本发明提供2,6,7本文所述的取代嘌呤或其药学上可接受的盐。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
Patent Agency Ranking
公开(公告)号：US20150353553A1
公开(公告)日：2015-12-10
申请号：US14762827
申请日：2014-01-29
Applicant: MERCK SHARP & DOHME CORP.
Inventor： Carolyn Michele Cammarano , Matthew P. Christopher , Christopher Dinsmore , Ronald J. Doll , Francesc Xavier Fradera Llinas , Chaomin Li , Michelle Machacek , Michelle Martinez , Latha G. Nair , Weidong Pan , Michael Hale Reutershan , Manami Shizuka , Dietrich P. Steinhuebel , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Yaolin Wang , Liping Yang , Stephane L. Bogen , Matthew E. Voss , Jagannath Panda , Anthappan Tony Kurissery
IPC: C07D473/34 , C07D473/16
CPC classification number: C07D473/00 , C07D473/16 , C07D473/30 , C07D473/34
Abstract: The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Abstract translation: 本发明提供如本文所述的2,6,7,8取代的嘌呤或其药学上可接受的盐。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
公开(公告)号：US20140357618A1
公开(公告)日：2014-12-04
申请号：US14465577
申请日：2014-08-21
Applicant: Merck Sharp & Dohme Corp.
Inventor： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Michael D. Altman , Stephane L. Bogen , Ronald J. Doll
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D471/08 , C07D498/04 , C07D519/00
Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Abstract translation: 本发明提供如本文所述的取代的咪唑并吡啶或其药学上可接受的盐或溶剂化物。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。
-
公开(公告)号：US20220363707A1
公开(公告)日：2022-11-17
申请号：US17266521
申请日：2019-08-05
Applicant: Merck Sharp & Dohme Corp. , MSD International GmbH
Inventor： Michelle Machacek , David Witter , Craig Gibeau , Chunhui Huang , Shuhei Kawamura , David L. Sloman , Phieng Siliphaivanh , Ryan Quiroz , Murray Wan , Sebastian Schneider , Charles S. Yeung , Michael H. Reutershan , Timothy J. Henderson , Jean-Laurent Paparin , Houcine Rahali , Jonathan M. E. Hughes , Sulagna Sanyal , Yingchun Ye , David A. Candito , Patrick S. Fier , Steven M. Silverman
IPC: C07H19/14 , C07D487/04 , A61P35/00
Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
-
公开(公告)号：US20210309688A1
公开(公告)日：2021-10-07
申请号：US17266507
申请日：2019-08-05
Applicant: Jongwon Lim , Michelle Machacek , Michael H. Reutershan , Sebastian Schneider , Merck Sharp & Dohme Corp.
Inventor： Jongwon Lim , Michelle Machacek , Michael H. Reutershan , Sebastian Schneider
IPC: C07H19/167 , C07D473/34 , C07D471/04
Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
-
公开(公告)号：US09682978B2
公开(公告)日：2017-06-20
申请号：US14764616
申请日：2014-02-04
Applicant: Merck Sharp & Dohme Corp.
Inventor： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Liping Yang
IPC: C07D473/30 , C07D473/34 , C07D473/00
CPC classification number: C07D473/34 , C07D473/00 , C07D473/30
Abstract: The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.039 seconds)
